- Home
- SGA vs ABVC Comparison
SGA vs ABVC Comparison
Compare SGA & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | ABVC |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 30.9M |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SGA | ABVC |
|---|---|---|
| Price | $11.74 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 48.5K |
| Earning Date | 03-12-2026 | 03-03-2026 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | $509,589.00 |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $10.68 | $0.74 |
| 52 Week High | $14.27 | $4.02 |
Technical Indicators
Market Signals| Indicator | SGA | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 35.36 |
| Support Level | $11.27 | N/A |
| Resistance Level | $11.99 | $1.67 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 70.76 | 29.19 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.